Vasopressin receptor antagonists: a patent summary (2018-2022)

References

• Laycock JF. Perspectives on Vasopressin. Imperial College Press: 2009. DOI:10.1142/p598
   Google Scholar
• Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab. 2000 Dec;11(10):406–410.
   PubMed Web of Science ®Google Scholar
• Hurbin A, Boissin-Agasse L, Orcel H, et al. The V1a and V1b, but not V2, vasopressin receptor genes are expressed in the supraoptic nucleus of the rat hypothalamus, and the transcripts are essentially colocalized in the vasopressinergic magnocellular neurons. Endocrinology. 1998;139(11):4701–4707.
   PubMed Web of Science ®Google Scholar
• Lolait SJ, O’Carroll AM, Mahan LC, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A. 1995;92(15):6783–6787. DOI:10.1073/pnas.92.15.6783
   PubMed Web of Science ®Google Scholar
• Ali F, Guglin M, Vaitkevicius P, et al. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847–858. DOI:10.2165/00003495-200767060-00002
   PubMed Web of Science ®Google Scholar
• Hunyady L, Vauquelin G, Vanderheyden P. Agonist induction and conformational selection during activation of a G-protein-coupled receptor. Trends Pharmacol Sci. 2003;24(2):81–86.
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Berti-Mattera LN, Dulin N, et al. Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Prog Brain Res. 1998;119:147–161.
   PubMed Web of Science ®Google Scholar
• Koshimizu TA, Nakamura K, Egashira N, et al. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92(4):1813–1864. doi:10.1152/physrev.00035.2011.
   PubMed Web of Science ®Google Scholar
• Narayen G, Mandal SN. Vasopressin receptor antagonists and their role in clinical medicine. Indian J Endocrinol Metab. 2012 Mar;16(2):183–191.
   PubMedGoogle Scholar
• Berl T. Vasopressin antagonists. N Engl J Med. 2015;372(23):2207–2216. doi:10.1056/NEJMra1403672.
   PubMed Web of Science ®Google Scholar
• Chaki S. Vasopressin V1B Receptor Antagonists as Potential Antidepressants. Int J Neuropsychopharmacol. 2021;24(6):450–463.
   PubMed Web of Science ®Google Scholar
• Torres VE. Vasopressin receptor antagonists, heart failure, and polycystic kidney disease. Annu Rev Med. 2015;66(1):195–210.
   PubMedGoogle Scholar
• Ślusarz MJ. Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014). Expert Opin Ther Pat. 2015;25(6):711–722. doi:10.1517/13543776.2015.1026257.
   PubMed Web of Science ®Google Scholar
• De Vecchis R, Cantatrione C, Mazzei D. Vasopressin receptor antagonists in patients with chronic heart failure. Vasopressinrezeptorantagonisten bei Patienten mit chronischer Herzinsuffizienz. Herz. 2017;42(5):492–497.
   PubMed Web of Science ®Google Scholar
• Ferris CF, Lu SF, Messenger T, et al. Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacol Biochem Behav. 2006;83(2):169–174. DOI:10.1016/j.pbb.2006.01.001
   PubMed Web of Science ®Google Scholar
• Ratni H, Rogers-Evans M, Bissantz C, et al. Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach. J Med Chem. 2015;58(5):2275–2289. doi:10.1021/jm501745f.
   PubMed Web of Science ®Google Scholar
• Lemmens-Gruber R, Kamyar M. Vasopressin antagonists. Cell Mol Life Sci. 2006;63(15):1766–1779.
   PubMed Web of Science ®Google Scholar
• Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371(9624):1624–1632.
   PubMed Web of Science ®Google Scholar
• Yirmiya N, Rosenberg C, Levi S, et al. Association between the arginine vasopressin 1a receptor (Avpr1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry. 2006;11(5):488–494. DOI:10.1038/sj.mp.4001812
   PubMed Web of Science ®Google Scholar
• A study of RO5028442 in adult male high-functioning autistic patients. ClinicalTrials. https://clinicaltrials.gov/ct2/show/record/NCT01474278
   Google Scholar
• Umbricht D, Del Valle Rubido M, Hollander E, et al. A single dose, Randomized, controlled proof-of-mechanism study of a novel Vasopressin 1a receptor Antagonist (RG7713) in high-functioning adults with autism spectrum disorder [published correction appears in Neuropsychopharmacology. Neuropsychopharmacology. 2017;42(9):1914–1923. 2017 Aug;42(9):1924]. DOI:10.1038/npp.2016.232.
   PubMed Web of Science ®Google Scholar
• Schnider P, Bissantz C, Bruns A, et al. Discovery of balovaptan, a vasopressin 1a receptor antagonist for the treatment of autism spectrum disorder. J Med Chem. 2020;63(4):1511–1525. doi:10.1021/acs.jmedchem.9b01478.
   PubMed Web of Science ®Google Scholar
• Bolognani F, Del Valle Rubido M, Squassante L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019;11(491):eaat7838. DOI:10.1126/scitranslmed.aat7838
   PubMed Web of Science ®Google Scholar
• Hollander E, Jacob S, Jou RJJ, et al. A phase 2 randomized controlled trial of Balovaptan in pediatric participants with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2020;59(10):S262–3. DOI:10.1016/j.jaac.2020.08.458
   Web of Science ®Google Scholar
• Jacob S, Veenstra-VanderWeele J, Murphy D, et al. PhAse 3 randomized controlled trial of balovaptan in adults with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2020;59(10):S163–4. DOI:10.1016/j.jaac.2020.08.108
   Web of Science ®Google Scholar
• Study to Evaluate The Safety and Efficacy of Balovaptan in Patients With Acute Ischemic Stroke at High Risk of Developing Malignant Brain Edema [cited 2023 Mar 27]. https://clinicaltrials.gov/ct2/show/NCT05399550
   Google Scholar
• Study to Evaluate The Efficacy and Safety of Balovaptan in Adults With Post-Traumatic Stress Disorder (PTSD). Available at: https://clinicaltrials.gov/ct2/show/NCT05401565 accessed on 27.03.2023
   Google Scholar
• Guillon CD, Koppel GA, Brownstein MJ, et al. Azetidinones as vasopressin V1a antagonists. Bioorg Med Chem. 2007;15(5):2054–2080. DOI:10.1016/j.bmc.2006.12.031
   PubMed Web of Science ®Google Scholar
• Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AV009). Available at: https://clinicaltrials.gov/ct2/show/NCT02055638 accessed on 27.03.2023
   Google Scholar
• Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington’s Disease. Available at: https://clinicaltrials.gov/ct2/show/NCT02507284 accessed on 27.03.2023
   Google Scholar
• Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD. Available at: https://clinicaltrials.gov/ct2/show/NCT02733614 accessed on 27.03.2023
   Google Scholar
• de Winter R.F, van Hemert A.M, DeRijk RH, et al. Anxious-retarded depression: relation with plasma vasopressin and cortisol [published correction appears in Neuropsychopharmacology. Neuropsychopharmacology. 2003;28(1):140–147. 2003 Mar;28(3):610]. DOI:10.1038/sj.npp.1300002.
   PubMed Web of Science ®Google Scholar
• Serradeil-Le Gal C, Wagnon J, Tonnerre B, et al. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev. 2005;11(1):53–68. DOI:10.1111/j.1527-3458.2005.tb00035.x
   PubMedGoogle Scholar
• Griebel G, Simiand J, Serradeil-Le Gal C, et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A. 2002;99(9):6370–6375. DOI:10.1073/pnas.092012099
   PubMed Web of Science ®Google Scholar
• Oost T, Backfisch G, Bhowmik S, et al. Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2011;21(12):3828–3831. DOI:10.1016/j.bmcl.2011.03.012
   PubMed Web of Science ®Google Scholar
• Hodgson RA, Mullins D, Lu SX, et al. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior. Eur J Pharmacol. 2014;730:157–163.
   PubMed Web of Science ®Google Scholar
• Hodgson RA, Higgins GA, Guthrie DH, et al. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav. 2007;86(3):431–440. DOI:10.1016/j.pbb.2006.12.021
   PubMed Web of Science ®Google Scholar
• A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder. Available at: https://clinicaltrials.gov/ct2/show/NCT03093025 accessed on 27.03.2023
   Google Scholar
• Kamiya M, Sabia HD, Marella J, et al. Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: a randomized, double-blind, placebo-controlled study. J Psychiatr Res. 2020;128:43–51.
   PubMed Web of Science ®Google Scholar
• Samsca (tolvaptan) FDA Approval History. Available at: https://www.drugs.com/history/samsca.html accessed on 27.03.2023
   Google Scholar
• Vaprisol FDA Approval History. Available at: https://www.drugs.com/history/vaprisol.html accessed on 27.03.2023
   Google Scholar
• Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287(3):860–867.
   PubMed Web of Science ®Google Scholar
• Aditya S, Rattan A. Vaptans: a new option in the management of hyponatremia. Int J Appl Basic Med Res. 2012;2(2):77–83.
   PubMedGoogle Scholar
• Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction. Available at: https://clinicaltrials.gov/ct2/show/NCT04331132 accessed on 27.03.2023
   Google Scholar
• Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH. Available at: https://clinicaltrials.gov/ct2/show/NCT05569655 accessed on 27.03.2023
   Google Scholar
• Serradeil-Le Gal C, Lacour C, Valette G, et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest. 1996;98(12):2729–2738. DOI:10.1172/JCI119098
   PubMed Web of Science ®Google Scholar
• Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol. 2006;1(6):1154–1160. DOI:10.2215/CJN.00160106
   PubMed Web of Science ®Google Scholar
• Ginès P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48(1):204–213. DOI:10.1002/hep.22293
   PubMed Web of Science ®Google Scholar
• Chan PS, Coupet J, Park HC, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol. 1998;449:439–443.
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ACTION). Available at: https://www.clinicaltrials.gov/ct2/show/NCT04064346 accessed on 27.03.2023
   Google Scholar
• Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104(20):2417–2423. DOI:10.1161/hc4501.099313
   PubMed Web of Science ®Google Scholar
• Gassanov N, Semmo N, Semmo M, et al. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol. 2011;67(4):333–346. DOI:10.1007/s00228-011-1006-7
   PubMed Web of Science ®Google Scholar
• Chen SY, Abrahams Z, Sokos GG, et al. Conivaptan: potential therapeutic implications in heart failure. Recent Pat Cardiovasc Drug Discov. 2008;3(2):137–140. DOI:10.2174/157489008784705403
   PubMedGoogle Scholar
• Fernández-Varo G, Ros J, Cejudo-Martín P, et al. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol. 2003;38(6):755–761. DOI:10.1016/S0168-8278(03)00116-8
   PubMed Web of Science ®Google Scholar
• Velez JC, Dopson SJ, Sanders DS, et al. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant. 2010;25(5):1524–1531. DOI:10.1093/ndt/gfp731
   PubMed Web of Science ®Google Scholar
• Seganish WM, Lynch JJ, Sorota S. Comprehensive Medicinal Chemistry. 3rd. ElsevierElsevier; 2017. Chapter 7.17p. 628–662.10.1016/B978-0-12-409547-2.12434-5.
   Google Scholar
• Kolkhof P, Pook E, Pavkovic M, et al. VasCular protection and decongestion without renin-angiotensin-aldosterone system stimulation mediated by a novel dual-acting vasopressin V1a/V2 receptor antagonist. J Cardiovasc Pharmacol. 2019;74(1):44–52.
   PubMed Web of Science ®Google Scholar
• Mondritzki T, Mai TA, Vogel J, et al. Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure. Eur J Heart Fail. 2021;23(5):743–750. DOI:10.1002/ejhf.2001
   PubMed Web of Science ®Google Scholar
• A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function. Available at: https://clinicaltrials.gov/ct2/show/NCT05599997 accessed on 27.03.2023
   Google Scholar
• Goldsmith SR, Burkhoff D, Gustafsson F, et al. Dual vasopressin receptor antagonism to improve congestion in patients with acute heart failure: design of the AVANTI trial. J Card Fail. 2021;27(2):233–241. DOI:10.1016/j.cardfail.2020.10.007
   PubMed Web of Science ®Google Scholar
• BlackThorn Therapeutics Inc. 1-(2-Azaspiro[3.3]heptan-6-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives as V1a receptor antagonists for treating neuropsychological disorders. WO2018226769
   Google Scholar
• BlackThorn Therapeutics Inc. Vasopressin receptor antagonists and products and methods related thereto. WO2019050988
   Google Scholar
• BlackThorn Therapeutics Inc. 1-(2,6-Diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders. WO2020123872
   Google Scholar
• Richter Gedeon Nyrt. Triazolobenzazepines as vasopressin V1a receptor antagonists. WO2019116324
   Google Scholar
• Richter Gedeon Nyrt. Tricyclic compounds as vasopressin V1a receptor antagonists. WO2019116325
   Google Scholar
• F. Hoffmann-La Roche AG. Heteroaryl-methyl substituted triazoles as vasopressin receptor V1a antagonists. WO2022018105 .
   Google Scholar
• F. Hoffmann-La Roche AG. Cyclohexyl substituted triazoles as vasopressin receptor V1a antagonists. WO2022018121
   Google Scholar
• Toa Eiyo Ltd. Vasopressin receptor antagonists. WO2019082910
   Google Scholar
• Shanghai Jemincare Pharmaceutical Co. Ltd. Novel benzazepine spiro derivatives. WO2022111581
   Google Scholar
• Shanghai Jemincare Pharmaceutical Co. Ltd. Triazole tricyclic derivatives and preparation method therefor and application thereof WO2022135335
   Google Scholar
• Shanghai Jemincare Pharmaceutical Co. Ltd. New-type benzazepine fused ring derivatives. WO2022184172
   Google Scholar
• Cao X, Wang P, Yuan H, et al. Benzodiazepine derivatives as potent vasopressin V2 receptor antagonists for the treatment of autosomal dominant kidney disease. J Med Chem. 2022;65(13):9295–9311. DOI:10.1021/acs.jmedchem.2c00567
   PubMedGoogle Scholar
• Xuzhou Medical University. Novel benzodiazepine compound, and composition and use thereof. WO2022156449.
   Google Scholar
• Xuzhou Medical University. Benzodiazepine pyrrole compound and preparation method and application thereof. CN114835716 (2022)
   Google Scholar
• Shanghai Senhui Pharmaceutical Co. Ltd. Benzazepine compounds and its preparation method and medical use. WO2022171160
   Google Scholar
• Bayer Pharma Aktiengesellschaft. Hydroxyalkyl-substituted triazole derivatives and uses thereof. WO2018073144
   Google Scholar
• Bayer Pharma Aktiengesellschaft. Amine substituted triazole derivatives and uses thereof. WO2019081299
   Google Scholar
• Bayer Pharma Aktiengesellschaft. Substituted triazole derivatives and uses thereof. WO2019081302
   Google Scholar
• Bayer Pharma Aktiengesellschaft. Substituted triazole derivatives and uses thereof. WO2019081303
   Google Scholar
• Bayer Pharma Aktiengesellschaft. Substituted triazole derivatives and uses thereof. WO2019081306
   Google Scholar
• Bayer Pharma Aktiengesellschaft. Substituted triazole derivatives and uses thereof. WO2019081307
   Google Scholar
• Bayer Pharma Aktiengesellschaft. Prodrugs of substituted triazole derivatives and uses thereof. WO2019081291
   Google Scholar
• Bayer Pharma Aktiengesellschaft. Prodrugs of substituted triazole derivatives and uses thereof. WO2019081292
   Google Scholar
• Shenzhen Salubris Pharmaceuticals Co. Ltd. Substituted 4-aryl-imidazole-2-ketone derivative and preparation method and medical use thereof. CN114835688 (2022)
   Google Scholar
• Otsuka Pharmaceutical Co.Ltd. Benzazepine derivatives. WO2019004421
   Google Scholar
• Derks M, Lennon-Chrimes S, Guenther A, et al. Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers. Expert Opin Investig Drugs. 2021;30(8):893–901. DOI:10.1080/13543784.2021.1948009
   PubMed Web of Science ®Google Scholar
• Jacob S, Veenstra-VanderWeele J, Murphy D, et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet Psychiatry. 2022;9(3):199–210. DOI:10.1016/S2215-0366(21)00429-6
   PubMed Web of Science ®Google Scholar
• Hollander E, Jacob S, Jou R, et al. Balovaptan vs Placebo for social communication in childhood autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(8):760–769. DOI:10.1001/jamapsychiatry.2022.1717
   PubMed Web of Science ®Google Scholar
• Jacob S, Anagnostou E, Hollander E, et al. Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program. Mol Autism. 2022;13(1):25. DOI:10.1186/s13229-022-00505-6
   PubMed Web of Science ®Google Scholar
• A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD). Available at: https://clinicaltrials.gov/ct2/show/NCT01793441?term=NCT01793441&draw=2&rank=1 accessed on 27.03.2023
   Google Scholar
• A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension. Available at: https://clinicaltrials.gov/ct2/show/NCT03504917?term=NCT03504917&draw=2&rank=1 accessed on 27.03.2023
   Google Scholar
• A study to Investigate the efficacy and safety of balovaptan (RO5285119) in participants with Autism Spectrum Disorder (ASD). Available at: https://clinicaltrials.gov/ct2/show/NCT02901431?term=NCT02901431&draw=2&rank=1 accessed on 27.03.2023
   Google Scholar
• Brownstein MJ, Simon NG, Long JD, et al. Safety and tolerability of SRX246, a Vasopressin 1a antagonist, in irritable Huntington’s disease patients-A randomized phase 2 clinical trial. J Clin Med. 2020;9(11):3682. DOI:10.3390/jcm9113682
   PubMed Web of Science ®Google Scholar
• Maibach HT, Brownstein MJ, Hersch SM, et al. The Vasopressin 1a receptor antagonist SRX246 reduces aggressive behavior in Huntington’s disease. J Pers Med. 2022;12(10):1561. DOI:10.3390/jpm12101561
   PubMed Web of Science ®Google Scholar
• Effects of SRX246 on an experimental model of fear and anxiety in humans. Available at: https://clinicaltrials.gov/ct2/show/NCT02922166?term=NCT02922166&draw=2&rank=1 accessed on 27.03.2023
   Google Scholar
• Clinical candidates, Azevan pharmaceuticals. Available at: https://azevan.com/pages/clinical-candidates-2/ accessed on 27.03.2023
   Google Scholar
• Our pipeline, Neumora. Available at: https://neumoratx.com/pipeline/ accessed on 27.03.2023
   Google Scholar
• FDA drug safety communication: fDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-duration-and-usage-samsca-tolvaptan-due-possible-liver accessed on 27.03.2023
   Google Scholar
• Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -receptor antagonist for the treatment of cardiac Edema. Available at: https://www.otsuka.co.jp/en/company/newsreleases/2022/20220328_1.html accessed on 27.03.2023
   Google Scholar
• Vasopressin V2 receptor antagonists disclosed by Toa Eiyo (May 17, 2019). Available at: https://www.bioworld.com/articles/671726-vasopressin-v2-receptor-antagonists-disclosed-by-toa-eiyo?v=preview accessed on 27.Mar.2023
   Google Scholar
• Jiangsu Hengrui Medicine and collaborators patent vasopressin V2 receptor antagonists (Sep 8, 2022). Available at: https://www.bioworld.com/articles/689456-jiangsu-hengrui-medicine-and-collaborators-patent-vasopressin-v2-receptor-antagonistsv=preview
   Google Scholar
• Development Pipeline, Bayer AG. Available at: https://www.bayer.com/en/pharma/development-pipeline accessed on 27.03.2023
   Google Scholar